This is a comprehensive presentation of the risks and benefits of radioiodine-131 in the
treatment of metastatic well differentiated thyroid cancer. In addition, methods to optimize the …

Post-surgical ablative iodine-131 therapy is recommended for all differentiated thyroid
cancer primary tumors> 1cm in diameter. Regarding smaller primary tumors, 131I ablation …

Background: I-131 has been used in the therapy of well-differentiated thyroid cancer for over
50 years. Although the benefits and risks of I-131 remain issues of controversy and research …

This article discusses several aspects of the evaluation and management of differentiated
thyroid carcinoma that are changing or may change in the near future. Although …

This article presents an overview of the use of radioactive iodine (131-I) in the treatment of
patients who have well differentiated thyroid cancer. We review definitions; staging; the two …

Radioiodine-131 has attained a significant role in the treatment of differentiated thyroid
cancer. The most favorable outcome can be expected when iodine-131 is used in …

Background: Publication of the 2015 American Thyroid Association (ATA) management
guidelines for adult patients with thyroid nodules and differentiated thyroid cancer was met …

The dosage of 131I for the treatment of metastatic well-differentiated thyroid cancer is
typically selected empirically. Benua and Leeper implemented a method to estimate the …

The use of radioactive iodine (131 I) for the treatment of thyroid carcinoma has changed over
the past 50 y. These changes are based on increasing awareness of the biophysical …

The therapeutic response and survival rates of 352 patients with differentiated thyroid
carcinoma who had received radioactive iodine therapy since 1951 were studied. Of these …